FDA Approves Abbott's Amplatzer ™ Talisman™ System for PFO Closure in People at Risk of Recurrent Stroke
- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide (Source: Abbott.com)
Source: Abbott.com - September 29, 2021 Category: Pharmaceuticals Source Type: news
Real-World Data Show Abbott's FreeStyle LibreLink App Users Spend More Time in Target Glucose Range Compared to Reader Users
- People with diabetes who use the FreeStyle Libre mobile app experience clinically significant improved time in target range (Source: Abbott.com)
Source: Abbott.com - September 28, 2021 Category: Pharmaceuticals Source Type: news
Abbott Hosts Conference Call for Third-Quarter Earnings
(Source: Abbott.com)
Source: Abbott.com - September 23, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Abbott's Epic ™ Plus Tissue Valves for People in Need of Mitral or Aortic Valve Replacement
- New enhancements to Abbott's Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures (Source: Abbott.com)
Source: Abbott.com - September 22, 2021 Category: Pharmaceuticals Source Type: news
Abbott Receives FDA Approval for Minimally Invasive Portico ™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
- Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery (Source: Abbott.com)
Source: Abbott.com - September 20, 2021 Category: Pharmaceuticals Source Type: news
Abbott Declares 391st Consecutive Quarterly Dividend
(Source: Abbott.com)
Source: Abbott.com - September 15, 2021 Category: Pharmaceuticals Source Type: news
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
Acquisition builds upon Abbott's leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots (Source: Abbott.com)
Source: Abbott.com - September 2, 2021 Category: Pharmaceuticals Source Type: news
Late-Breaking Data Shows Abbott's Amplatzer ™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
- New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device (Source: Abbott.com)
Source: Abbott.com - August 30, 2021 Category: Pharmaceuticals Source Type: news
GUIDE-HF Study Data Show Abbott's CardioMEMS ™ Device Can Improve Care for More Patients with Heart Failure
- The GUIDE-HF study examined the potential impact of Abbott's CardioMEMS ™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device (Source: Abbott.com)
Source: Abbott.com - August 27, 2021 Category: Pharmaceuticals Source Type: news
Abbott's Amplatzer ™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
- Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation (Source: Abbott.com)
Source: Abbott.com - August 16, 2021 Category: Pharmaceuticals Source Type: news
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
- Ultreon ™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence (Source: Abbott.com)
Source: Abbott.com - August 3, 2021 Category: Pharmaceuticals Source Type: news
Abbott's FreeStyle ® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2] (Source: Abbott.com)
Source: Abbott.com - August 2, 2021 Category: Pharmaceuticals Source Type: news
Abbott Introduces Jot Dx ™ Insertable Cardiac Monitor, Designed to Reduce Data Burden and Improve Accurate Diagnosis of Difficult-to-Detect Abnormal Heart Rhythms
- Jot Dx ™ Insertable Cardiac Monitor (ICM) expands Abbott's connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic (Source: Abbott.com)
Source: Abbott.com - July 29, 2021 Category: Pharmaceuticals Source Type: news
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
- Patients with diabetes who did not meet the recommended daily intake of protein had greater physical limitations, which together may suggest an increased risk of muscle loss (Source: Abbott.com)
Source: Abbott.com - July 29, 2021 Category: Pharmaceuticals Source Type: news
Abbott Reports Second-Quarter 2021 Results
- Sales growth of 39.5 percent; organic sales growth of 35.0 percent (Source: Abbott.com)
Source: Abbott.com - July 22, 2021 Category: Pharmaceuticals Source Type: news
